The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial
Authors:
- 1 October 2019
- journal article
- research article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 8 (5) , 575-583
Abstract
Background: Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303 trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell lung cancer (NSCLC) patients. Meanwhile, the impact of previous therapy strategies on the efficiency of anlotinib still remains unknown. Methods: The subgroup of patients in ALTER0303 were analyzed by using Kaplan-Meier estimates, Pearson χ2, or Fisher’s exact test. Results: There was no statistical significance on progression-free survival (PFS) and overall survival (OS) among patients in different previous antiangiogenic treatments groups. Patients in the chest radiotherapy (CRT) group had longer median PFS than the non-CRT group (5.93 vs. 4.63 m, P=0.027). Regardless of what kind of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) and chemotherapy regimens were used previously, all patients gained longer PFS in the anlotinib group, while only patients treated with vinorelbine/platinum in the EGFR wild type group, pemetrexed/platinum, vinorelbine/platinum, and gefitinib in the EGFR mutation group, and EGFR TKI used as the first line group could benefit from anlotinib on OS. When the OS was calculated from the time of diagnosis to the death, anlotinib could have increased median OS about 6 months (33.8 vs. 27.8 m, PConclusions: This study indicated that previous bevacizumab or endostatin treatments had no impact on the efficiency of anlotinib. Patients with CRT history benefited more from anlotinib on PFS. EGFR TKI and chemotherapy treatment history had more impact on OS than PFS in patients treated with anlotinib compared to placebo.Keywords
This publication has 22 references indexed in Scilit:
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCNew England Journal of Medicine, 2018
- Cancer treatment and survivorship statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challengesCancer Letters, 2015
- A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapyLung Cancer, 2014
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Therapeutic options targeting angiogenesis in nonsmall cell lung cancerEuropean Respiratory Review, 2014
- Radiation and immunotherapy: a synergistic combinationJournal of Clinical Investigation, 2013
- Lung Cancer in ChinaChest, 2013
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III TrialJournal of Clinical Oncology, 2012